**Cardiac Toxicity of Chemotherapy**
=====================================

**Core Concept**
---------------

The patient's symptoms and examination findings suggest cardiac dysfunction, likely due to the cardiotoxic effects of chemotherapy agents, specifically anthracyclines like doxorubicin. Anthracyclines can cause direct damage to cardiac myocytes, leading to impaired cardiac function and potentially heart failure.

**Why the Correct Answer is Right**
---------------------------------

Doxorubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting the enzyme topoisomerase II and causing double-strand breaks. This leads to the generation of reactive oxygen species (ROS), which can damage cardiac myocytes and lead to cardiotoxicity. The patient's symptoms, such as exertional dyspnea, peripheral edema, and orthopnea, are consistent with heart failure. The presence of an S3 gallop and an S4 gallop on examination suggests ventricular dysfunction.

**Why Each Wrong Option is Incorrect**
--------------------------------------

**Option A:** This option is incorrect as it does not directly relate to the cardiotoxic effects of chemotherapy agents. While hypertension can contribute to cardiac dysfunction, it is not the most likely cause in this scenario.

**Option B:** This option is incorrect as it does not specifically address the cardiotoxic effects of anthracyclines. While radiation therapy can cause cardiac toxicity, it is not the primary cause in this patient.

**Option C:** This option is incorrect as it is not directly related to the patient's symptoms or examination findings. While anemia can contribute to symptoms such as fatigue and shortness of breath, it is not the most likely cause of the patient's cardiac condition.

**Clinical Pearl / High-Yield Fact**
---------------------------------

Anthracyclines can cause cardiotoxicity, which can be exacerbated by other factors such as radiation therapy, hypertension, and concomitant use of other cardiotoxic agents. Patients treated with anthracyclines should be closely monitored for signs of cardiac dysfunction, and cardioprotective agents such as dexrazoxane may be considered to reduce the risk of cardiotoxicity.

**Correct Answer:** C.